US5095026A
(en)
*
|
1983-02-04 |
1992-03-10 |
University Of Iowa Research Foundation |
Prodrugs of carbonic anhydrase inhibitors
|
US5200180A
(en)
*
|
1987-06-26 |
1993-04-06 |
Christian Bannert |
Pharmaceutical composition for the treatment of the human eye
|
FR2618333B1
(fr)
*
|
1987-07-20 |
1990-07-13 |
Merck Sharp & Dohme |
Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
|
US5843156A
(en)
|
1988-08-24 |
1998-12-01 |
Endoluminal Therapeutics, Inc. |
Local polymeric gel cellular therapy
|
US6436425B1
(en)
|
1988-11-16 |
2002-08-20 |
Mdv Technologies, Inc. |
Method and non-gelling composition for inhibiting post-surgical adhesions
|
US4911926A
(en)
*
|
1988-11-16 |
1990-03-27 |
Mediventures Inc. |
Method and composition for reducing postsurgical adhesions
|
US5034406A
(en)
*
|
1989-09-26 |
1991-07-23 |
Allergan, Inc. |
Method for reducing or maintaining intraocular pressure
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
FR2653021A1
(fr)
*
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
|
FR2653018A1
(fr)
|
1989-10-17 |
1991-04-19 |
Merck Sharp & Dohme |
Composition ophtalmique non solide a base de microparticules de polymere contenant au moins un principe actif en suspension dans un milieu dispersant et procede de preparation de ladite composition.
|
US5141928B1
(en)
*
|
1989-12-20 |
1995-11-14 |
Brujo Inc |
Ophthalmic medication
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
FR2657018A1
(fr)
*
|
1990-01-12 |
1991-07-19 |
Merck Sharp & Dohme |
Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
|
US5593683A
(en)
*
|
1990-05-01 |
1997-01-14 |
Mdv Technologies, Inc. |
Method of making thermoreversible polyoxyalkylene gels
|
US5298260A
(en)
*
|
1990-05-01 |
1994-03-29 |
Mediventures, Inc. |
Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
US5346703A
(en)
|
1990-08-07 |
1994-09-13 |
Mediventures, Inc. |
Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
|
CA2044878C
(en)
*
|
1990-08-07 |
2000-12-26 |
Tacey X. Viegas |
Thermally reversible and irreversible gels
|
FR2665635A1
(fr)
*
|
1990-08-10 |
1992-02-14 |
Merck Sharp & Dohme |
Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
|
US5847023A
(en)
*
|
1990-10-26 |
1998-12-08 |
Mdv Technologies, Inc. |
Thermal irreversible gel corneal contact lens formed in situ
|
EP0495421B1
(de)
*
|
1991-01-15 |
1996-08-21 |
Alcon Laboratories, Inc. |
Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
ZA927277B
(en)
*
|
1991-10-02 |
1993-05-19 |
Boston Ocular Res |
Dry eye treatment process and solution.
|
US5318780A
(en)
*
|
1991-10-30 |
1994-06-07 |
Mediventures Inc. |
Medical uses of in situ formed gels
|
RU2108112C1
(ru)
*
|
1993-04-16 |
1998-04-10 |
Вакамото Фармасьютикал Ко., Лтд. |
Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
US5545617A
(en)
*
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
JP2742333B2
(ja)
*
|
1994-05-06 |
1998-04-22 |
アルコン ラボラトリーズ,インコーポレイテッド |
眼科用組成物におけるビタミンeトコフェリル誘導体の使用
|
IL114193A
(en)
*
|
1994-06-20 |
2000-02-29 |
Teva Pharma |
Ophthalmic pharmaceutical compositions based on sodium alginate
|
US5585398A
(en)
*
|
1994-07-15 |
1996-12-17 |
Ernst; Amy A. |
Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
|
US6316443B1
(en)
|
1994-08-04 |
2001-11-13 |
Merck & Co., Inc. |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
|
US5827835A
(en)
*
|
1994-08-30 |
1998-10-27 |
Alcon Laboratories, Inc. |
Thermally-gelling emulsions
|
US5618800A
(en)
*
|
1994-08-30 |
1997-04-08 |
Alcon Laboratories, Inc. |
Thermally-gelling drug delivery vehicles containing cellulose ethers
|
US5516808A
(en)
*
|
1994-10-27 |
1996-05-14 |
Sawaya; Assad S. |
Topical cellulose pharmaceutical formulation
|
US5603929A
(en)
*
|
1994-11-16 |
1997-02-18 |
Alcon Laboratories, Inc. |
Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
|
US6165490A
(en)
*
|
1996-04-05 |
2000-12-26 |
Staar Surgical Ag |
Biological material, method of preparing such materials, uses thereof and products made therefrom
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US5843470A
(en)
*
|
1995-10-06 |
1998-12-01 |
Mdv Technologies, Inc. |
Method and composition for inhibiting post-surgical adhesions
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
US6610292B2
(en)
*
|
1995-11-22 |
2003-08-26 |
Ista Pharmaceuticals, Inc. |
Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
|
US5866120A
(en)
*
|
1995-11-22 |
1999-02-02 |
Advanced Corneal Systems, Inc. |
Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
|
US5641532A
(en)
*
|
1995-12-15 |
1997-06-24 |
The Procter & Gamble Company |
Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum
|
WO1997029777A1
(fr)
|
1996-02-13 |
1997-08-21 |
Dainippon Pharmaceutical Co., Ltd. |
Systeme d'administration de medicament utilisant une galactoxyloglucane
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
US5888493A
(en)
*
|
1996-12-05 |
1999-03-30 |
Sawaya; Assad S. |
Ophthalmic aqueous gel formulation and related methods
|
EP0971641A4
(de)
*
|
1997-04-03 |
2003-08-13 |
Point Biomedical Corp |
System zur verabreichung von einem intravesikalen arzneimittel
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
AU737442B2
(en)
*
|
1997-07-29 |
2001-08-16 |
Alcon Laboratories, Inc. |
Ophthalmic compositions containing galactomannan polymers and borate
|
AU8570498A
(en)
|
1997-07-29 |
1999-02-22 |
Alcon Laboratories, Inc. |
Switchable viscoelastic systems containing galactomannan polymers and borate
|
DE69826730T2
(de)
*
|
1997-07-29 |
2005-02-10 |
Alcon Laboratories, Inc., Fort Worth |
Konditionierungslösungen für die Pflege von harten Kontaktlinsen
|
US20040063678A1
(en)
*
|
1997-10-06 |
2004-04-01 |
Bausch & Lomb Incorporated |
Dexamethasone Gel
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
US6312666B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of whitening teeth
|
US6312667B1
(en)
*
|
1998-11-12 |
2001-11-06 |
3M Innovative Properties Company |
Methods of etching hard tissue in the oral environment
|
US6669927B2
(en)
|
1998-11-12 |
2003-12-30 |
3M Innovative Properties Company |
Dental compositions
|
EA004050B1
(ru)
*
|
1998-12-11 |
2003-12-25 |
Бакулиш Мафатлал Хамар |
Способ изготовления состава местных бета-блокаторов улучшенного действия
|
EP1616869B1
(de)
*
|
1999-01-25 |
2012-04-04 |
National Jewish Health |
Substituierte Porphyrine und deren therapeutische Verwendung
|
ATE243038T1
(de)
|
1999-11-01 |
2003-07-15 |
Alcon Inc |
Pharmazeutische zusammensetzungen ein fluorchinolonantibiotikum und xanthangummi enthaltend
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
MXPA03000813A
(es)
|
2000-07-28 |
2005-08-16 |
Alcon Inc |
Composiciones farmaceuticas que contienen tobramicina y goma de xantano.
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
JP2002154989A
(ja)
*
|
2000-11-14 |
2002-05-28 |
Lion Corp |
眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
|
US20090258955A1
(en)
*
|
2000-12-20 |
2009-10-15 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
WO2002049610A2
(en)
*
|
2000-12-20 |
2002-06-27 |
Alcon, Inc. |
Ophthalmic irrigating solution adapted for use in lasik surgery
|
PT1343474E
(pt)
*
|
2000-12-20 |
2010-04-19 |
Alcon Inc |
Solução de irrigação intra-ocular com características de fluidez aperfeiçoadas
|
JP4169596B2
(ja)
*
|
2000-12-20 |
2008-10-22 |
アルコン、インコーポレイテッド |
白内障を液化破壊により取り除くための溶液
|
US7084130B2
(en)
*
|
2001-12-11 |
2006-08-01 |
Alcon, Inc. |
Intraocular irrigating solution having improved flow characteristics
|
AU2002232437A1
(en)
*
|
2000-12-20 |
2002-07-01 |
Alcon Universal Ltd. |
Ophthalmic lubricating solution adapted for use in lasik surgery
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20020172712A1
(en)
*
|
2001-03-19 |
2002-11-21 |
Alan Drizen |
Antiemetic, anti-motion sustained release drug delivery system
|
AU2002312194B8
(en)
*
|
2001-06-01 |
2008-05-15 |
Aeolus Sciences, Inc. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
ATE404193T1
(de)
*
|
2001-06-05 |
2008-08-15 |
Ronald Aung-Din |
Topische migränetherapie
|
US8329734B2
(en)
*
|
2009-07-27 |
2012-12-11 |
Afgin Pharma Llc |
Topical therapy for migraine
|
US20080199524A1
(en)
*
|
2001-08-10 |
2008-08-21 |
Toray Industries, Inc. |
Eyedrops containing particulate agar
|
EP1424081A4
(de)
|
2001-08-10 |
2005-09-21 |
Toray Industries |
Polysaccharidhaltige zusammensetzungen und ihre verwendung
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
AU2002359301B2
(en)
*
|
2001-10-23 |
2008-07-03 |
Comentis, Inc. |
Beta-secretase inhibitors and methods of use
|
US6620405B2
(en)
|
2001-11-01 |
2003-09-16 |
3M Innovative Properties Company |
Delivery of hydrogel compositions as a fine mist
|
JP2005521690A
(ja)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
ゴム系を含む眼科用製剤
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
US7030149B2
(en)
*
|
2002-04-19 |
2006-04-18 |
Allergan, Inc. |
Combination of brimonidine timolol for topical ophthalmic use
|
US7642258B2
(en)
*
|
2002-04-19 |
2010-01-05 |
Allergan, Inc. |
Combination of brimonidine and timolol for topical ophthalmic use
|
CA2484797A1
(en)
*
|
2002-05-06 |
2003-11-13 |
Washington University |
Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
NZ540885A
(en)
*
|
2002-12-20 |
2009-02-28 |
Chakshu Res Inc |
Ophthalmic formulation for the prevention and treatment of ocular conditions
|
US20060172972A1
(en)
*
|
2002-12-20 |
2006-08-03 |
Chakshu Research Inc |
Formulation and method for administration of ophthalmologically active agents
|
US20060177430A1
(en)
*
|
2002-12-20 |
2006-08-10 |
Chakshu Research Inc |
Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
|
US20060166879A1
(en)
*
|
2002-12-20 |
2006-07-27 |
Chakshu Research Inc |
Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
|
GB0300531D0
(en)
*
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
US20070065463A1
(en)
*
|
2003-06-20 |
2007-03-22 |
Ronald Aung-Din |
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
|
CN1878571B
(zh)
*
|
2003-11-10 |
2010-09-08 |
东丽株式会社 |
含有多糖类的组合物及泪液层稳定化滴眼剂
|
US20050129770A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Alcon, Inc. |
Ophthalmic compositions containing a PVA/borate gelling system
|
WO2005060933A1
(en)
*
|
2003-12-11 |
2005-07-07 |
Alcon, Inc. |
Ophthalmic compositions containing a polysaccharide/borate gelling system
|
JP4771044B2
(ja)
*
|
2004-09-15 |
2011-09-14 |
大正製薬株式会社 |
粘膜適用液剤
|
US20080207527A1
(en)
*
|
2004-09-17 |
2008-08-28 |
Comentis, Inc. |
Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
|
EP1799660A2
(de)
*
|
2004-09-17 |
2007-06-27 |
Comentis, Inc. |
Aminohaltige verbindungen zur inhibition der aktivität von memapsin-2-beta-sekretase und verfahren zu ihrer verwendung
|
US20080096859A1
(en)
*
|
2004-10-01 |
2008-04-24 |
Sullivan Kathleen A |
Compositions and Methods for Treating Ophthalmic Diseases
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
US20070059274A1
(en)
*
|
2004-12-01 |
2007-03-15 |
Bahram Asgharian |
Ophthalmic compositions containing a PVA/borate gelling system
|
WO2006083927A2
(en)
*
|
2005-01-31 |
2006-08-10 |
Coram Bioscience, Inc. |
Antimicrobial agent
|
KR20080015079A
(ko)
*
|
2005-04-08 |
2008-02-18 |
코멘티스, 인코포레이티드 |
베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
|
AU2006270094A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Chakshu Research Inc. |
Prevention and treatment of ophthalmic complications of diabetes
|
US7534795B2
(en)
*
|
2005-10-25 |
2009-05-19 |
Allergan, Inc. |
Compounds and their use related to compositions for treating disease
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
CA2633655A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Comentis, Inc. |
Topical mecamylamine formulations for ocular administration and uses therof
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
KR100802534B1
(ko)
|
2006-06-13 |
2008-02-14 |
주식회사태준제약 |
저자극성 점안제 조성물 및 이의 제조 방법
|
WO2008005457A2
(en)
|
2006-06-30 |
2008-01-10 |
Sunesis Pharmaceuticals |
Pyridinonyl pdk1 inhibitors
|
HUE043228T2
(hu)
|
2007-06-22 |
2019-08-28 |
Univ Texas |
Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
|
EP2178837A2
(de)
*
|
2007-07-26 |
2010-04-28 |
Comentis, Inc. |
Isophthalamidderivate als hemmer der beta-sekretase-aktivität
|
MX2010002938A
(es)
*
|
2007-09-24 |
2010-04-01 |
Comentis Inc |
Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
|
MX2010009857A
(es)
*
|
2008-03-07 |
2010-12-07 |
Sun Pharma Advanced Res Co Ltd |
Composicion oftalmica.
|
CA2725012C
(en)
|
2008-05-23 |
2019-05-07 |
National Jewish Health |
Methods for treating injury associated with exposure to an alkylating species
|
WO2010005507A1
(en)
|
2008-06-30 |
2010-01-14 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
WO2010031056A2
(en)
|
2008-09-15 |
2010-03-18 |
The Regents Of The University Of California |
Methods and compositions for modulating ire1, src, and abl activity
|
JP2010132587A
(ja)
*
|
2008-12-03 |
2010-06-17 |
Teika Seiyaku Kk |
眼科用剤
|
US8580947B2
(en)
|
2009-02-05 |
2013-11-12 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
US8470997B2
(en)
*
|
2009-02-05 |
2013-06-25 |
Gene Signal International Sa |
Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
|
RU2482851C2
(ru)
*
|
2009-02-20 |
2013-05-27 |
Микро Лабс Лимитед |
Хранение стабильного продукта простагландина
|
MX353747B
(es)
|
2009-08-17 |
2018-01-26 |
Memorial Sloan Kettering Cancer Center Star |
Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
CA2771822C
(en)
|
2009-09-04 |
2020-08-11 |
Daniel A. Erlanson |
Bruton's tyrosine kinase inhibitors
|
US8679511B2
(en)
*
|
2009-10-01 |
2014-03-25 |
Duquesne University of the Holy Spririt |
In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
|
CN102665718B
(zh)
|
2009-10-06 |
2016-03-09 |
米伦纽姆医药公司 |
可用作pdk1抑制剂的杂环化合物
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
PT2853262T
(pt)
|
2009-10-26 |
2017-01-31 |
Sephoris Pharmaceuticals Llc |
Tratamento de queimaduras solares usando analgésicos e anti-histamínicos
|
CA2781056A1
(en)
|
2009-11-16 |
2011-05-19 |
Rebecca Maglathlin |
Kinase inhibitors
|
WO2011072257A2
(en)
|
2009-12-10 |
2011-06-16 |
The Regents Of The University Of California |
Amyloid binding agents
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
DE102010009475B4
(de)
|
2010-02-26 |
2011-11-24 |
F. Holzer Gmbh |
Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
|
CA2829790C
(en)
|
2010-03-30 |
2018-06-05 |
Verseon Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
JP2013523828A
(ja)
|
2010-04-07 |
2013-06-17 |
アラーガン インコーポレイテッド |
眼科用組成物のための保存剤の組み合わせ
|
US20110250294A1
(en)
|
2010-04-07 |
2011-10-13 |
Allergan, Inc. |
Combinations of preservative compositions for ophthalmic formulations
|
JP5713791B2
(ja)
*
|
2010-05-12 |
2015-05-07 |
テイカ製薬株式会社 |
眼科用剤
|
US20130149394A1
(en)
|
2010-08-27 |
2013-06-13 |
Wakamoto Pharmaceutical Co., Ltd. |
Aqueous ophthalmic composition
|
US8530449B2
(en)
|
2010-09-09 |
2013-09-10 |
Assad S. Sawaya |
Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
|
SG10201507554RA
(en)
|
2010-09-13 |
2015-10-29 |
Bev Rx Inc |
Aqueous drug delivery system comprising off - flavor masking agent
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
JP5885271B2
(ja)
|
2011-02-14 |
2016-03-15 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
ビマトプロストのエステル誘導体の組成物および方法
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
JP6068451B2
(ja)
|
2011-05-17 |
2017-01-25 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア |
キナーゼ阻害剤
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
AU2012279154A1
(en)
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
EP2751112B1
(de)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituierte pyrazolo[3,4-d]pyrimidine und ihre verwendung
|
CA2853729A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
EP2836482B1
(de)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von krebs
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
EP2858500A4
(de)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
Hemmer der bruton-tyrosinkinase
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
EP2888239B1
(de)
|
2012-08-27 |
2018-11-28 |
Allergan, Inc. |
Reduzierung der verdickung der zentralen hornhaut durch verwendung hydrophiler ester-prodrugs von beta-chlorcyclopentanen
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Compounds of pyrazolopyrimidine, as kinase inhibitors
|
BR112015006828A8
(pt)
|
2012-09-26 |
2019-09-17 |
Univ California |
composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
|
EP2909214B1
(de)
|
2012-10-22 |
2020-07-22 |
City of Hope |
Etp-derivate
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
EP2953950B1
(de)
|
2013-02-11 |
2021-01-13 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
EP2968296B1
(de)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gammasekretasemodulatoren
|
US9295665B2
(en)
|
2013-03-12 |
2016-03-29 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
|
ES2877898T3
(es)
|
2013-03-14 |
2021-11-17 |
Univ California |
Agentes mucolíticos de tiosacáridos
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
EP2968270A4
(de)
|
2013-03-14 |
2016-08-17 |
Univ California |
Modulation von k2p-kanälen
|
BR112015023214A8
(pt)
|
2013-03-15 |
2019-12-24 |
Verseon Corp |
composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
|
BR112015023705A8
(pt)
|
2013-03-15 |
2020-03-17 |
Univ California |
compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
|
BR112015021859A2
(pt)
|
2013-03-15 |
2017-07-18 |
Allergan Inc |
bimatoprost para potencialização da produção de leptina
|
CA2904794C
(en)
|
2013-03-15 |
2021-11-23 |
Peter Walter |
Modulators of the eif2alpha pathway
|
JP6397479B2
(ja)
|
2013-03-15 |
2018-09-26 |
エータイアー ファーマ, インコーポレイテッド |
ヒスチジル−tRNAシンテターゼFcコンジュゲート
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
SG10201707480PA
(en)
|
2013-03-15 |
2017-10-30 |
Verseon Corp |
Multisubstituted aromatic compounds as serine protease inhibitors
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
HUE053282T2
(hu)
|
2013-08-19 |
2021-06-28 |
Univ California |
Vegyületek és eljárások epilepsziás rendellenesség kezelésére
|
WO2015026935A2
(en)
|
2013-08-20 |
2015-02-26 |
City Of Hope |
Hdac8 inhibitors for treating cancer
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
MY179781A
(en)
|
2013-12-11 |
2020-11-13 |
Biogen Ma Inc |
Biaryl inhibitors of bruton's tyrosine kinase
|
US10280169B2
(en)
|
2013-12-11 |
2019-05-07 |
Biogen Ma Inc. |
Biaryl bruton's tyrosine kinase inhibitors
|
CN106456645B
(zh)
|
2013-12-23 |
2021-03-23 |
纪念斯隆-凯特琳癌症中心 |
用于放射性标记的方法和试剂
|
EP3091985A4
(de)
|
2014-01-10 |
2017-11-29 |
Manistee Partners LLC |
Behandlung von migränen
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
HRP20220759T1
(hr)
|
2014-02-11 |
2022-09-02 |
Mitokinin, Inc. |
Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
|
CA2937752C
(en)
|
2014-02-14 |
2023-02-07 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
AU2015259752B2
(en)
|
2014-02-20 |
2019-06-20 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
CA2939186C
(en)
|
2014-02-21 |
2023-03-07 |
Principia Biopharma Inc. |
Salts and solid form of a btk inhibitor
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
AU2015235929B2
(en)
|
2014-03-26 |
2019-02-14 |
City Of Hope |
Treatment of BRCA1-defective cancer or resistant cancers
|
EP3129354B1
(de)
|
2014-04-07 |
2022-01-05 |
The Regents of the University of California |
Inhibitoren des enzyms der fettsäureamidhydrolase (faah) mit verbesserter oraler bioverfügbarkeit und deren verwendung als arzneimittel
|
BR112016026470A8
(pt)
|
2014-05-13 |
2021-07-20 |
Memorial Sloan Kettering Cancer Center |
composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
US9012402B1
(en)
|
2014-06-11 |
2015-04-21 |
James Blanchard |
Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
WO2016023036A1
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
High density peptide polymers
|
CA2960992A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
Mtorc1 inhibitors
|
KR20230145550A
(ko)
|
2014-09-15 |
2023-10-17 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
뉴클레오타이드 유사체
|
BR112017004704A2
(pt)
|
2014-09-17 |
2018-01-23 |
Verseon Corp |
composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
CN111978310A
(zh)
|
2014-10-02 |
2020-11-24 |
阿勒根公司 |
γ-内酰胺的酯前药及其用途
|
WO2016061147A1
(en)
|
2014-10-13 |
2016-04-21 |
John Eric Paderi |
Luminal vessel coating for arteriovenous fistula
|
WO2016061145A1
(en)
|
2014-10-13 |
2016-04-21 |
Symic Biomedical, Inc. |
Synthetic proteoglycans for preventing tissue adhesion
|
WO2016065083A1
(en)
|
2014-10-21 |
2016-04-28 |
Symic Biomedical, Inc. |
Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
|
WO2016100914A1
(en)
|
2014-12-18 |
2016-06-23 |
Gourlay Steven |
Treatment of pemphigus
|
US10689423B2
(en)
|
2015-01-13 |
2020-06-23 |
City Of Hope |
CTLA4-binding protein peptide-linker masks
|
CN113797349A
(zh)
|
2015-01-16 |
2021-12-17 |
希望之城 |
细胞穿透抗体
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
EA201992474A3
(ru)
|
2015-02-25 |
2020-05-31 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Агонисты 5ht для лечения нарушений
|
AU2016224975B2
(en)
|
2015-02-27 |
2020-10-22 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvanation
|
LT3261639T
(lt)
|
2015-02-27 |
2022-11-25 |
Verseon International Corporation |
Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
|
CA2977521C
(en)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
|
US10383816B2
(en)
|
2015-03-02 |
2019-08-20 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoid combination products
|
US10716766B2
(en)
|
2015-03-02 |
2020-07-21 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoids
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
BR112017021869A2
(pt)
|
2015-04-10 |
2018-12-11 |
Araxes Pharma Llc |
compostos quinazolina substituídos e métodos de uso dos mesmos
|
MX2017013275A
(es)
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
WO2016166604A1
(en)
|
2015-04-17 |
2016-10-20 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
EP3286214B1
(de)
|
2015-04-24 |
2023-12-06 |
The Regents of the University of California |
Modulatoren der ror1-ror2-bindung
|
CN114990141A
(zh)
|
2015-05-15 |
2022-09-02 |
希望之城 |
嵌合抗原受体组合物
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
US20180282310A1
(en)
|
2015-06-10 |
2018-10-04 |
Biogen Ma Inc. |
Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
CA2991052A1
(en)
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
WO2017024238A1
(en)
|
2015-08-06 |
2017-02-09 |
City Of Hope |
Cell penetrating protein-antibody conjugates and methods of use
|
EP3128007A1
(de)
|
2015-08-07 |
2017-02-08 |
Gene Signal International SA |
Sterile emulsion mit einem stabilen phosphorothioat-oligonukleotid
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
US11124483B2
(en)
|
2015-09-02 |
2021-09-21 |
The Regents Of The University Of California |
HER3 ligands and uses thereof
|
JP6933644B2
(ja)
|
2015-09-04 |
2021-09-08 |
シティ・オブ・ホープCity of Hope |
アンドロゲン受容体拮抗薬
|
WO2017051251A1
(en)
|
2015-09-25 |
2017-03-30 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
TW201718028A
(zh)
|
2015-10-13 |
2017-06-01 |
賽米克Ip有限責任公司 |
Ve-鈣黏蛋白結合性生物結合物
|
US10801026B2
(en)
|
2015-10-15 |
2020-10-13 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤をスクリーニングするための方法
|
BR112018008025A2
(pt)
|
2015-10-23 |
2018-10-23 |
Sunesis Pharmaceuticals, Inc. |
inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer
|
BR112018008103A2
(pt)
|
2015-10-23 |
2018-11-06 |
Erx Pharmaceuticals, Inc. |
análogos de celastrol
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US20190119259A1
(en)
|
2015-12-10 |
2019-04-25 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
DK3394046T3
(da)
|
2015-12-24 |
2022-04-04 |
Univ California |
Cftr-regulatorer og fremgangsmåder til anvendelse deraf
|
ES2909316T3
(es)
|
2015-12-24 |
2022-05-06 |
Univ California |
Reguladores de CFTR y métodos de uso de los mismos
|
JP6931002B2
(ja)
|
2016-01-05 |
2021-09-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ベンゾチアゾール両親媒性物質
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
WO2017161344A1
(en)
|
2016-03-17 |
2017-09-21 |
The Regants Of The University Of California |
Compositions and methods for treating parasitic diseases
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
GR1009006B
(el)
|
2016-04-01 |
2017-04-04 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
|
GR1009040B
(el)
|
2016-04-19 |
2017-05-19 |
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων |
Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
|
PT3458448T
(pt)
|
2016-04-25 |
2021-09-10 |
Forma Therapeutics Inc |
Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica
|
US20210323913A1
(en)
|
2016-04-29 |
2021-10-21 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
KR102243775B1
(ko)
|
2016-05-12 |
2021-04-22 |
아나코르 파마슈티칼스 인코포레이티드 |
옥사보롤 에스터 및 이의 용도
|
US10918648B2
(en)
|
2016-05-26 |
2021-02-16 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
CA3028169A1
(en)
|
2016-06-29 |
2018-01-04 |
Principia Biopharma Inc. |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
WO2018013609A2
(en)
|
2016-07-11 |
2018-01-18 |
The Regents The University Of California |
Synthetic melanin nanoparticles uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク. |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
US20180049994A1
(en)
|
2016-08-16 |
2018-02-22 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with caryophyllene
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
EP3512565A4
(de)
|
2016-09-13 |
2020-05-06 |
The Jackson Laboratory |
Gezielte dna-demethylierung und -methylierung
|
EP3512520B1
(de)
|
2016-09-15 |
2023-06-21 |
City of Hope |
Dithio-derivate von epidithiodiketopiperazine (etp)
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
WO2018112420A1
(en)
|
2016-12-15 |
2018-06-21 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
EP3573971A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-on-derivate und ähnliche verbindungen als kras-g12c-modulatoren zur behandlung von krebs
|
EP3573967A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
|
EP3573954A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
|
US10052343B1
(en)
|
2017-02-03 |
2018-08-21 |
Gene Signal International Sa |
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
EP3576753B1
(de)
|
2017-02-03 |
2024-04-17 |
Laboratoires KÔL |
Sterile emulsion enthaltend einen stabilen phosphorothioat-oligonukleotid
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
WO2018218070A2
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
US11414419B2
(en)
|
2017-06-21 |
2022-08-16 |
Mitokinin, Inc. |
Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
US10821075B1
(en)
|
2017-07-12 |
2020-11-03 |
James Blanchard |
Compositions for topical application of a medicaments onto a mammalian body surface
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
EP3688028A2
(de)
|
2017-09-29 |
2020-08-05 |
Genentech, Inc. |
Antibiotische peptidkomplexe und verfahren zu deren verwendung
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
JP2020536920A
(ja)
|
2017-10-10 |
2020-12-17 |
サイロス ファーマシューティカルズ, インコーポレイテッド |
ピロロトリアジン化合物およびtamキナーゼを阻害する方法
|
WO2019079819A1
(en)
|
2017-10-20 |
2019-04-25 |
City Of Hope |
COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
BR112020008834A2
(pt)
|
2017-11-02 |
2020-12-22 |
Calico Life Sciences Llc |
Moduladores da via de estresse integrada
|
CA3080959A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
EP3704098B1
(de)
|
2017-11-02 |
2024-01-24 |
Calico Life Sciences LLC |
Modulatoren eines integrierten spannungswegs
|
JP7307057B2
(ja)
|
2017-11-02 |
2023-07-11 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
MX2020004538A
(es)
|
2017-11-02 |
2020-09-18 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
AU2018358157B2
(en)
|
2017-11-02 |
2023-03-09 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
RU2020118594A
(ru)
|
2017-11-06 |
2021-12-09 |
Рапт Терапьютикс, Инк. |
Противораковые агенты
|
CN111698989B
(zh)
|
2017-12-07 |
2023-08-01 |
安普利克斯制药公司 |
杂环取代的吡啶衍生物抗真菌剂
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
EP3740206B1
(de)
|
2018-01-16 |
2024-03-06 |
Syros Pharmaceuticals, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
WO2019143719A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
EP3765459A1
(de)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituierte imidazopyridine als inhibitoren von plasmakallikrein und verwendungen davon
|
EP3784233A4
(de)
|
2018-04-27 |
2022-03-02 |
Spruce Biosciences, Inc. |
Verfahren zur behandlung von hoden-und eierstock-nebennierentumoren
|
CA3098698A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
US20190336609A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
|
US11931345B2
(en)
|
2018-05-04 |
2024-03-19 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
|
WO2019236631A1
(en)
|
2018-06-05 |
2019-12-12 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
KR102533477B1
(ko)
|
2018-06-21 |
2023-05-18 |
칼리코 라이프 사이언시스 엘엘씨 |
단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
|
JP2021530445A
(ja)
|
2018-06-25 |
2021-11-11 |
アンプリックス ファーマシューティカルズ,インク. |
複素環およびアミノ基によって置換されたピリジン誘導体
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
EP3856742A4
(de)
|
2018-11-01 |
2022-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclische janus-kinase-1-inhibitoren und zusammensetzungen und verfahren dafür
|
CN113242734A
(zh)
*
|
2018-11-26 |
2021-08-10 |
艾葳生物科技有限公司 |
用于药物递送的药用生物可溶凝胶
|
JP7204005B2
(ja)
|
2019-03-14 |
2023-01-13 |
カリコ ライフ サイエンシーズ エルエルシー |
タンパク質チロシンホスファターゼ阻害物質及びその使用方法
|
AU2020264485A1
(en)
|
2019-04-30 |
2021-12-02 |
Abbvie Inc. |
Substituted cycloalkyls as modulators of the integrated stress pathway
|
FR3095592B1
(fr)
*
|
2019-05-02 |
2021-05-21 |
Unither Pharmaceuticals |
Composition à base de gomme gellane et de phényléphrine, procédé de fabrication et utilisation comme produit ophtalmique
|
US10973780B2
(en)
|
2019-05-15 |
2021-04-13 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
BR112022004475A2
(pt)
|
2019-09-18 |
2022-05-31 |
Novartis Ag |
Proteínas de fusão nkg2d e usos das mesmas
|
JP2022548696A
(ja)
|
2019-09-18 |
2022-11-21 |
武田薬品工業株式会社 |
血漿カリクレインインヒビター及びその使用
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
WO2021097339A1
(en)
|
2019-11-13 |
2021-05-20 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
AU2020407648A1
(en)
|
2019-12-18 |
2022-06-30 |
Abbvie Inc. |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
EP4126076A1
(de)
|
2020-03-31 |
2023-02-08 |
Sentiss Pharma Private Limited |
Sterilisationsverfahren von timololgelbildender lösung durch aseptische filtration
|
GR1010024B
(el)
|
2020-05-06 |
2021-06-01 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
|
EP4153564A1
(de)
|
2020-05-19 |
2023-03-29 |
Cybin IRL Limited |
Deuterierte tryptaminderivate und verfahren zur verwendung
|
KR20230053611A
(ko)
|
2020-08-18 |
2023-04-21 |
사이빈 아이알엘 리미티드 |
펜에틸아민 유도체, 조성물, 및 사용 방법
|
PE20231656A1
(es)
|
2020-11-02 |
2023-10-17 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
|
CA3198795A1
(en)
|
2020-11-18 |
2022-05-27 |
Jeffrey Becker |
Complexing agent salt formulations of pharmaceutical compounds
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
KR20240004296A
(ko)
|
2021-03-17 |
2024-01-11 |
다께다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인의 헤테로아릴 억제제
|
JP2024510502A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインのイミダゾピリジニル阻害剤
|
WO2022197756A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors
|
EP4308229A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasmakallikreinhemmer
|
WO2022197789A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Polycyclic inhibitors of plasma kallikrein
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|